works in treating younger patients with recurrent, refractory, or progressive juvenile
pilocytic astrocytomas or optic nerve pathway gliomas. Lenalidomide may stop the growth of
tumor cells by blocking blood flow to the tumor.
For more information about a clinical trial, clinical trial eligibility, or informed consent, contact our research nurses by phone or email:
- Cancer Help Line: (800) 639-6918
- Email: firstname.lastname@example.org
Please Note: Any eligibility criteria noted are subject to change. Our research nurses can provide you with the most current eligibility and exclusion criteria. Any study involvement to be undertaken must ultimately be determined on an individual basis.